Primary prophylaxis with pegylated G-CSF is associated with improved treatment completion and progression-free survival in locally advanced cervical cancer undergoing concurrent chemoradiotherapy: a retrospective cohort study

BACKGROUND: Concurrent cisplatin-based chemoradiotherapy (CCRT) for locally advanced cervical cancer is often limited by severe neutropenia. This study evaluated whether primary prophylaxis with pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) improves outcomes. METHODS: = 160). The cohort included patients on various platinum-based regimens to reflect real-world practice; regimen heterogeneity was addressed as a covariate in adjusted analyses. Endpoints included grade 3-4 neutropenia, treatment delivery, and survival. RESULTS: = 0.094). CONCLUSIONS: In this retrospective analysis, primary prophylaxis with PEG-rhG-CSF was associated with reduced severe neutropenia, better adherence to planned CCRT, and longer progression-free survival. These findings support its consideration within standard supportive care for this population and warrant prospective validation.